Teva
Sunday 6 April 2025
(13:00-13:45 CEST)
Madrid Hall
in person live-streamed
Industry Satellite SymposiumThrough the looking glass: Tardive dyskinesia in the age of modern psychiatry
Chair: Prof. Stefan Leucht, Germany
| 13:00-13:05 | Welcome and introductions | Prof. Stefan Leucht, Germany |
| 13:05-13:20 | The invisible made visible – Prevalence and diagnosis of TD | Sofia Pappa, UK |
| 13:20-13:35 | Living with TD: From patient stories to personalized care plan | Andrew Cutler, USA |
| 13:35-13:45 | Discussion | Prof. Stefan Leucht, Germany |
Otsuka Pharmaceutical Europe Ltd.
Sunday 6 April 2025
(13:00-13:45 CEST)
Paris Hall
in person live-streamed
Industry Satellite SymposiumRewiring the Mind: Neuroplasticity and Digital Innovations in Managing Depressive Disorder
Chair: Allan Young, UK
| 13:00-13:05 | Welcome and introductions | Allan Young, UK |
| 13:05-13:20 | Leveraging neuroplasticity in MDD: From unmet needs to therapeutic advances | Prof. Berhard Baune, Germany |
| 13:20-13:35 | Expanding treatment options for depressive disorder: Results from the Mirai Phase 3 Trial | Allan Young, UK |
| 13:35-13:40 | Q&A | All |
| 13:40-13:45 | Summary and Close | Allan Young, UK |
Johnson and Johnson
Sunday 6 April 2025
(13:15-14:45 CEST)
Auditorio A
in person live-streamed
Industry Satellite Symposium
A holistic view of the management of MDD/TRD: From guidelines to patient perspectives
Chair: Eduard Vieta, Spain and Roger McIntyre, Canada
| 13:15-13:20 | Welcome & introduction | Eduard Vieta, Spain |
| 13:20-13:35 | Using recommendations from clinical guidelines and current research to optimise management of patients with MDD/TRD | Eduard Vieta, Spain |
| 13:35-13:55 | Factors influencing the management of MDD/TRD | Roger McIntyre, Canada |
| 13:55-14:25 | Importance of patient reported outcomes when treating patients with MDD/TRD | Rocio Gómez-Juanes, Spain and Marco Di Nicola, Italy |
| 14:25-14;40 | Audience Q&A | All |
| 14:40-14:45 | Closing remarks | Roger McIntyre, Canada |
Boehringer Ingelheim
Sunday 6 April 2025
(13:15-14:45 CEST)
Rome Hall
in person live-streamed
Industry Satellite Symposium
Optimising schizophrenia care: From early detection to comprehensive treatment pathways
Chair: Jose Manuel Olivares, Spain
| 13:15-13:40 | Unseen challenges: Living with schizophrenia | Jose Manuel Olivares, Spain |
| 13:40-14:05 | Schizophrenia symptom domains explored: From recognition in the clinic to impact on daily living | Charlotte Emborg, Denmark |
| 14:05-14:30 | Rethinking the care pathway for schizophrenia | Peter Falkai, Germany |
| 14:30-14:45 | Live Q&A | Maria Tajes Alonso, Spain |
Dr. Willmar Schwabe GmbH & Co. KG
Sunday 6 April 2025
(14:00-14:45 CEST)
Madrid Hall
in person live-streamed
Industry Satellite Symposium
Enhancing patient benefit: Real-world data and evidence in MCI and dementia
Chair: Mercè Boada, Spain
| 14:00-14:05 | Introduction | Mercè Boada, Spain |
| 14:05-14:20 | The added value of real-world data in MCI and dementia care | Robert Perneczky, Germany |
| 14:20-14:40 | How patients benefit from real-world evidence on MCI and dementia drugs | María Sagrario Manzano Palomo, Spain |
| 14:40-14:45 | Live Q&A | All |
Otsuka Pharmaceutical Europe Ltd.
Sunday 6 April 2025
(14:00-14:45 CEST)
Paris Hall
in person live-streamed
Industry Satellite SymposiumAdvancing schizophrenia treatment: Aligning innovative treatment formulations with patient goals
Chair: Christoph Correll, Germany
| 14:00-14:05 | Welcome and Introduction | Christoph Correll, Germany |
| 14:05-14:20 | Optimising antipsychotic development: The role of pharmacokinetic bridging in reducing relapse risk and patient burden | David Taylor, United Kingdom |
| 14:20-14:35 | Translating data to treatment: How pharmacokinetic Insights can inform clinical efficacy for schizophrenia | Christoph Correll, Germany |
| 14:35-14:40 | Q&A | All |
| 14:40-14:45 | Summary and close | Christoph Correll, Germany |
Viatris
Monday 7 April 2025
(13:00-13:45 CEST)
Auditorio A
in person live-streamed
Industry Satellite Symposium
Redefining recovery: Targeted treatment strategies for depression and anxiety
| 13:00-13:20 | Personalised pathways to freedom from anxiety | Andrea Fagiolini, Italy |
| 13:20-13:40 | Build up the MDD puzzle: A symptom-driven approach to treatment | Roger McIntyre, Canada |
| 13:40-13:45 | Q&A session | All |
Dr. Willmar Schwabe GmbH & Co. KG
Monday 7 April 2025
(13:00-13:45 CEST)
Rome Hall
in person live-streamed
Industry Satellite Symposium
Optimising quality of life outcomes in the treatment of anxiety disorders
Chair: Siegfried Kasper, Austria
| 13:00-13:05 | Introduction | Siegfried Kasper, Austria |
| 13:05-13:40 | Patients’ perspective on helpfulness of treatment and outcomes of pharmacotherapy in anxiety disorders | Markus Dold, Austria |
| 13:40-13:45 | Q&A | All |
Gedeon Richter & Recordati
Monday 7 April 2025
(13:00-13:45 CEST)
Londres Hall
in person
Industry Satellite Symposium
Partial activity, full impact: Innovations in schizophrenia treatment
Chair: José Martínez-Raga, Spain
| 13:00-13:05 | Introduction | José Martínez-Raga, Spain |
| 13:05-13:20 | MoA matters: Differentiating the mechanisms of partial agonists | Stephan Hjorth, Sweden |
| 13:20-13:35 | Bridging mechanisms and outcomes: Insights into symptom management | Giovanni Martinotti, Italy |
| 13:35-13:45 | Live Q&A | All |
Idorsia
Monday 7 April 2025
(13:15-14:45 CEST)
Paris Hall
in person
Industry Satellite Symposium
Unravelling the complexities of chronic insomnia with comorbid depression or anxiety: A practical guide to management
Chair: Eduard Vieta, Spain
| 13:15-13:30 | The burden of chronic insomnia in the psychiatric patient | Eduard Vieta, Spain |
| 13:30-13:35 | Patient case part 1 | Hugh Selsick, UK |
| 13:35-13:50 | Diagnostic challenges and clinical guidelines | Hugh Selsick, UK |
| 13:50-13:55 | Patient case part 2 | Laura Palagini, Italy |
| 13:55-14:10 | Emerging real-world data on daridorexant for the treatment of chronic insomnia with psychiatric comorbidities | Laura Palagini, Italy |
| 14:10-14:25 | Depression and anxiety with chronic insomnia: A holistic approach to treatment | Pierre-Alexis Geoffroy, France |
| 14:25-14:30 | Patient case part 3 | Pierre-Alexis Geoffroy, France |
| 14:30-14:45 | Q&A and panel discussion | All |
Johnson and Johnson
Monday 7 April 2025
(13:15-14:45 CEST)
Madrid Hall
in person live-streamed
Industry Satellite Symposium
It’s about time: Improving outcomes in schizophrenia
Chair and Co-Chair: Ana González-Pinto, Spain and David Taylor, United Kingdom
| 13:15-13:30 | Welcome and introduction | Ana González-Pinto, Spain |
| 13:30-13:50 | Avoiding delay: How early use of LATs can improve long-term patient outcomes | David Taylor, United Kingdom |
| 13:50-14:10 | Sustaining disease control over time: Advantages of very long-acting treatments vs. LATs | Sergio Benavente-López, Spain |
| 14:10-14:30 | Timely engagement: Empowering patients and caregivers through shared decision-making | Carlo Ignazio Cattaneo, Italy |
| 14:30-14:42 | Panel discussion | All |
| 14:42-14:45 | Closing remarks | Ana González-Pinto, Spain |
Teva
Monday 7 April 2025
(14:00-14:45 CEST)
Rome Hall
in person live-streamed
Industry Satellite SymposiumThe pursuit of uninterrupted treatment and early intervention for schizophrenia
Chair: Dr. Andrew Cutler, USA
| 14:00-14:05 | Welcome and Introductions | Dr. Andrew Cutler, USA |
| 14:05-14:20 | Long-acting injectable (LAI) antipsychotics, roadmap for better adherence and early intervention in schizophrenia | Carmen Moreno, Spain |
| 14:20-14:35 | Subcutaneous Olanzapine LAI in Schizophrenia – Initial Results from the Phase III SOLARIS Study | Christoph Correll, USA |
| 14:35-14:45 | Discussion | Dr. Andrew Cutler, USA |
Biogen
Monday 7 April 2025
(14:00-14:45 CEST)
Auditorio A
in person live-streamed
Industry Satellite SymposiumPostpartum depression: Elevating awareness, understanding impact, and recognising unmet needs
Chair: Jose Antonio Ramos Quiroga, University Hospital Vall d’Hebron, Barcelona, Spain
| 14:00-14:05 | Welcome and introductions | Jose Antonio Ramos Quiroga, Spain |
| 14:05-14:11 | Recognising postpartum depression | Jose Antonio Ramos Quiroga, Spain |
| 14:11-14:23 | Understanding risk factors for postpartum depression and its Impact on the patient, child and family | Amaury Cantilino, Brazil |
| 14:23-14:35 | Unmet needs in early recognition and management of postpartum depression | Igor Emanuel, Brazil |
| 14:35-14:45 | Q&A and closing remarks | ALL |
Laboratorios Farmacèuticos ROVI
Monday 7 April 2025
(18:45-19:30 CEST)
Paris Hall
in person
Industry Satellite Symposium
Addressing unmet needs in schizophrenia: Implementing LAIs into clinical care
Chair: Andrea Fiorillo, Italy
| 18:45-18:50 | Introduction | Andrea Fiorillo, Italy |
| 18:50-19:05 | Part I | Maximillian Huhn, Germany |
| 19:05-19:20 | Part II | Christoph Correll, Germany |
| 19:20-19:30 | Q&A | All |
